Open AccessLong lasting octreotide LAR therapy in large cell neuroendocrine carcinoma (LCNEC) of the lung
Author(s) -
Alfredo Butera
Publication year - 2015
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i1s.1066
Subject(s) - medicine , octreotide , chemotherapy , oncology , neuroendocrine carcinoma , lung cancer , adjuvant chemotherapy , lung , adjuvant therapy , neuroendocrine tumors , carcinoma , adjuvant , cancer , somatostatin , breast cancer
In this article we report a case of a patient with large cell neuroendocrine carcinoma (LCNEC) of the lung. Patients with LCNEC usually have poor prognosis and the benefit of adjuvant chemotherapy for these patients has not been fully established. This case suggests that octreotide LAR, a somatostatine analogue (SSA), can be useful in the treatment of neuroendocrine carcinoma also as maintenance therapy in association with chemotherapy. Further studies, regarding individual tumour biological behaviour and SSAs optimal dosage, could be useful to optimise treatment and to add new insights into the mechanisms of action and the role of SSAs in the therapy of NETs.